Understanding how the immune system responds to gene therapy for muscle diseases
Mechanism of immune response to muscle-directed AAV gene transfer
This study is looking at how the immune system reacts to a special treatment using viruses to help people with serious muscle diseases like Duchenne muscular dystrophy, so we can make the therapy safer and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11076740 on NIH RePORTER |
What this research studies
This research investigates the immune responses that occur when using adeno-associated viral (AAV) vectors for gene therapy aimed at treating severe muscle degenerative disorders like Duchenne muscular dystrophy (DMD). By examining how the immune system reacts to these vectors, the researchers aim to identify challenges that may limit the effectiveness of the therapy, such as the formation of neutralizing antibodies and cytotoxic T cell responses. The study involves collaboration between experts in immune mechanisms and translational research, utilizing animal models to better understand these responses and improve treatment outcomes for patients. The goal is to enhance the safety and efficacy of AAV gene transfer in muscle therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with severe muscle degenerative disorders, particularly Duchenne muscular dystrophy.
Not a fit: Patients with muscle disorders not related to AAV gene therapy or those who have contraindications to gene therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer gene therapies for patients with muscle degenerative disorders.
How similar studies have performed: Previous research has shown promise in understanding immune responses to AAV vectors, indicating that this approach could lead to significant advancements in gene therapy.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Herzog, Roland W. — Indiana University Indianapolis
- Study coordinator: Herzog, Roland W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.